Karyopharm Therapeutics | KPTI - 流动负债



金融业
股票价格
USD
资产
USD 108.42M
现金及等价物
USD 60.54M
销售成本
USD 1.48M
流动资产
USD 103.15M
流动负债
USD 92.06M
债务
USD 299.23M
股息收益率
0
EBIT
USD -17.84M
EBITDA
USD -26.2M
员工
325
EPS每股收益
USD -2.22
股本和储备
USD -292.93M
销售毛利
USD 32.6M
债务利息支出
USD 12.62M
利息收入
USD -0.15
贷款资金
USD 278.22M
市值
USD 1.09B
净收入
USD -102.2M
营业费用
USD 51.92M
营业利润
USD -17.84M
普通股股本
USD 18.31M
税前利润
USD -39.9M
销售收入
USD 34.08M
销售和管理费用
USD 9.56M
股票
USD 4.04M
贸易债权人
USD 4M
应收帐款人
USD 26.18M


流动负债 更改 日
AbbVie USD 42.1B 1.19B 2026-03
Abbott USD 18.38B 1.88B 2026-03
Amgen USD 24.96B 534M 2026-03
AstraZeneca USD 32.57B 1.95B 2026-03
BioCryst Pharmaceuticals USD 195.39M 675K 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Eli Lilly USD 36.63B 1.41B 2026-03
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
Incyte USD 1.49B 25.52M 2026-03
J&J USD 57.72B 3.59B 2026-03
Karyopharm Therapeutics USD 92.06M 4.9M 2025-12
MacroGenics USD 95.94M 52.82M 2026-03
Merck USD 26.94B 1.38B 2026-03
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Novartis USD 31.37B 4.1B 2026-03
Novartis USD 27.28B 4.72B 2025-12
Pfizer USD 34.35B 2.64B 2026-03
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Roche Holding CHF 28B 421M 2025-12
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Takeda JPY 2.43T 180.65B 2026-03
Tectonic Therapeutic USD 12.96M 3.29M 2026-03
TG Therapeutics USD 187.11M 33.35M 2026-03
Ultragenyx Pharmaceutical USD 325M 59M 2026-03
Xencor USD 73.46M 22.45M 2026-03